Phospho-Stat3 (Tyr705) rabbit mAb PE conjugate Antibody

Considered an oncogene, Stat3 is constitutively active in 70% of solid and hematological tumors, including leukemia, lymphoma, and multiple myeloma. The IL-6-Jak-Stat3 pathway can mediate cancer inflammation through both mutation of key regulatory genes and environmental stressors. Attempts at directly targeting Stat3 in cancer therapy have focused on the development of phosphopeptides and mimics that interact with the phospho-tyrosine-SH2 domain of Stat3 in an effort to destabilize active dimers and prevent DNA binding. Stat3 is primarily phosphorylated at Tyr705 upon activation of the Jak-Stat3 pathway. Secondary phosphorylation at Tyr727 at the C-terminus is thought to occur after Tyr705 phosphorylation. However, studies in melanoma have shown constitutive phosphorylation at Tyr727 that promotes survival of these cancerous cells.